Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DAXXIFY · 1 trial · 1 indication
• The proportion of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS
• The proportion of subjects achieving a score of 0 (none) or 1 (mild) in FHL severity at maximum contraction (maximum eyebrow elevation) at Week 4 as assessed by the IGA-FHWS
| Arm | Type | Description |
|---|---|---|
| Active Treatment (DAXXIFY) | EXPERIMENTAL | All subjects will receive DAXXIFY for injection as IM injections. |
| Name | Type | Description |
|---|---|---|
| DAXXIFY | DRUG | Intramuscular injection of daxibotulintoxinA-lanm |
Inclusion Criteria: 1. Be outpatient, male or female subjects, in good general health, 18 years of age or older 2. Have a score of moderate (2) or severe (3) GL during maximum contraction as assessed by the IGA-FWS 3. Have a score of moderate (2) or severe (3) FHL during maximum contraction as asse...
DAXXIFY is used for glabellar frown lines, the vertical wrinkles between the eyebrows. It is being studied as a treatment for this dermatologic condition. The drug is currently in clinical development and is not yet approved for this use.
DAXXIFY is a small molecule that targets the underlying muscle activity that causes glabellar frown lines. It works by reducing the muscle contractions that create these wrinkles, though the specific molecular target is not disclosed.
DAXXIFY is developed by Revance Therapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol RVNC.
DAXXIFY is in Phase 2 clinical development. It has completed one Phase 2a trial for glabellar frown lines, and the drug remains investigational as it is still being studied.
DAXXIFY has one completed clinical trial, NCT06411002, a Phase 2a study in dynamic forehead lines and glabellar lines. The trial enrolled 27 participants in the United States and was uncontrolled, meaning there was no control group.
Yes, DAXXIFY is the same as DaxibotulinumtoxinA-lanm. The clinical trial NCT06411002 refers to the drug as DaxibotulinumtoxinA-lanm for injection, and DAXXIFY is the brand name for this product.